HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells to extend healthy lifespan.
heXem bio has raised $10.4M in total funding. The most recent round was Seed. The last funding was announced in March 2026.
heXem bio's investors include Gaingels, Alumni Ventures, Draper Associates, Seraphim Space, ZAKA VC.
heXem bio is headquartered in Los Angeles, United States.
HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells to extend healthy lifespan.
heXem bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"heXem bio — Funding & Investors." VCBacked, March 28, 2026, https://www.vcbacked.co/company/hexem-bio. Accessed August 14, 2026.
VCBacked. (2026). heXem bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/hexem-bio
{{cite web |title=heXem bio — Funding & Investors |url=https://www.vcbacked.co/company/hexem-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated